Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date December 16, 2025 · Filed December 17, 2025
Section 16 reporting ended · disclosed 2025-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 567,580 |
Reported balance
After 2025-12-16 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-12-16 · Other · Disposed 43,499 · Balance 567,580 F1: Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 93,750 |
Reported balance
Holding disclosure · report date 2025-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 93,750 F2: This is based upon the 93,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 93,750 shares. Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein.
F2: This is based upon the 93,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 93,750 shares. Ms. Hendricks disclaims beneficial ownership of the 93,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 17, 2025 15:42 UTC | Monopar Therapeutics MNPR · Entity 5152 | OtherCommon Stock | 43,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-038139 · rdgdoc.xml · nonDerivative · entry 1 Hendricks Diane · CIK 0001727478 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 567,580 F1 · kind: Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein. F1 · ownership.nature: Reported disposition relates to pro rata distribution by Gem Pharmaceuticals, LLC ("Gem") to its members in which the reporting person has no pecuniary interest. Pharma Investments LLC ("Pharma") owns a controlling share of Gem and the reporting person, a manager of Gem, owns a controlling share of Pharma, so Pharma and its controlling shareholders have indirect control over the securities described herein. The managers of Gem and the controlling shareholders of Pharma each disclaim ownership of the shares of common stock owned by Gem, except to the extent of their pecuniary interest therein. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 19:10 UTC | Monopar Therapeutics MNPR · Entity 5152 | PurchaseCommon stock | 468,750 | $8.00 | $3,750,000.00 |
DisclosureSEC source: 0001654954-19-014155 · section16.xml · nonDerivative · entry 1 Hendricks Diane · CIK 0001727478 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 468,750 F1 · ownership.nature: This is based upon the 468,750 shares of Monopar Common Stock that DMH Business LLC directly owns. As a manager of DMH Business LLC, Ms. Hendricks may be deemed to share voting and dispositive power over these 468,750 shares. Ms. Hendricks disclaims beneficial ownership of the 468,750 shares held by DMH Business LLC, except to the extent of her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.